Viemed Healthcare US (VMD) has released an update.
Viemed Healthcare has reported a strong start to 2024 with first-quarter revenues up 28% to $50.6 million and a 21% increase in Adjusted EBITDA, reflecting the company’s successful operational enhancements and strategic growth efforts. With a robust cash balance and no net debt, the company is well-positioned for future expansion, including a new joint venture that underscores its role as a leader in home healthcare innovations. Looking forward, Viemed anticipates continued revenue growth in the second quarter of 2024.
For further insights into VMD stock, check out TipRanks’ Stock Analysis page.
